| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Omnicell has a current Overall Rating of A (Highest Rating). | 7 |
$25 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for OMCL. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: OMNICELL -- OMCL | 1 |
$4 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| OMCL: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | OMNICELL INC (OMCL=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Computer & Peripheral Intelligence Monitor: overall outlook VERY STRONG - 25 new Leaders; 4 new Laggards. | 44 |
$20 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for OMCL | 13 |
$25 |
| 23-Nov-2009 | Market Edge |
N/A
| Market Edge Equity Research Report | 4 |
$10 |
| 22-Nov-2009 | Wright Reports |
N/A
| Wright Industry Averages: Health, Medicine and Pharmaceuticals (United States) | 101 |
$169 |
| 22-Nov-2009 | Wright Reports |
N/A
| Wright Industry Averages: Health, Medicine and Pharmaceuticals (North America) | 103 |
$169 |
1.48% Nasdaq 
Research Reports
